Casey Woodring
Stock Analyst at JP Morgan
(1.77)
# 3,367
Out of 5,245 analysts
72
Total ratings
34.21%
Success rate
-8.47%
Average return
Main Sectors:
Stocks Rated by Casey Woodring
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Maintains: Neutral | $175 → $120 | $116.78 | +2.76% | 7 | May 18, 2026 | |
| TXG 10x Genomics | Maintains: Neutral | $17 → $20 | $23.68 | -15.54% | 2 | May 12, 2026 | |
| ALMR Alamar Biosciences | Initiates: Overweight | $30 | $20.06 | +49.55% | 1 | May 12, 2026 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,413 → $1,200 | $1,103.09 | +8.79% | 2 | May 11, 2026 | |
| CAI Caris Life Sciences | Maintains: Overweight | $35 → $30 | $15.55 | +92.93% | 1 | May 8, 2026 | |
| NTRA Natera | Maintains: Overweight | $260 → $265 | $203.19 | +30.42% | 4 | May 8, 2026 | |
| GH Guardant Health | Maintains: Overweight | $130 → $135 | $118.95 | +13.49% | 4 | May 8, 2026 | |
| BLLN BillionToOne | Maintains: Overweight | $120 → $125 | $85.92 | +45.48% | 3 | May 7, 2026 | |
| RVTY Revvity | Maintains: Neutral | $96 → $90 | $96.95 | -7.17% | 2 | May 6, 2026 | |
| RGEN Repligen | Maintains: Overweight | $180 → $165 | $115.06 | +43.40% | 1 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $330 → $345 | $342.37 | +0.77% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $125 | $144.41 | -13.44% | 4 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $45 | $35.17 | +27.95% | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $165 → $160 | $160.30 | -0.19% | 11 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $60 | $46.18 | +29.93% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $255 → $225 | $167.90 | +34.01% | 2 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $45.69 | +20.38% | 1 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $180 | $114.96 | +56.58% | 2 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $22 | $11.86 | +85.50% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $15.71 | +1.88% | 3 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $12 | $8.12 | +47.78% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $600 → $650 | $448.28 | +45.00% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $3.61 | +66.20% | 3 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $25 → $23 | $26.19 | -12.18% | 2 | Oct 31, 2023 |
ICON Public Limited Company
May 18, 2026
Maintains: Neutral
Price Target: $175 → $120
Current: $116.78
Upside: +2.76%
10x Genomics
May 12, 2026
Maintains: Neutral
Price Target: $17 → $20
Current: $23.68
Upside: -15.54%
Alamar Biosciences
May 12, 2026
Initiates: Overweight
Price Target: $30
Current: $20.06
Upside: +49.55%
Mettler-Toledo International
May 11, 2026
Maintains: Neutral
Price Target: $1,413 → $1,200
Current: $1,103.09
Upside: +8.79%
Caris Life Sciences
May 8, 2026
Maintains: Overweight
Price Target: $35 → $30
Current: $15.55
Upside: +92.93%
Natera
May 8, 2026
Maintains: Overweight
Price Target: $260 → $265
Current: $203.19
Upside: +30.42%
Guardant Health
May 8, 2026
Maintains: Overweight
Price Target: $130 → $135
Current: $118.95
Upside: +13.49%
BillionToOne
May 7, 2026
Maintains: Overweight
Price Target: $120 → $125
Current: $85.92
Upside: +45.48%
Revvity
May 6, 2026
Maintains: Neutral
Price Target: $96 → $90
Current: $96.95
Upside: -7.17%
Repligen
May 6, 2026
Maintains: Overweight
Price Target: $180 → $165
Current: $115.06
Upside: +43.40%
May 6, 2026
Maintains: Neutral
Price Target: $330 → $345
Current: $342.37
Upside: +0.77%
May 1, 2026
Maintains: Neutral
Price Target: $120 → $125
Current: $144.41
Upside: -13.44%
Apr 29, 2026
Maintains: Overweight
Price Target: $60 → $45
Current: $35.17
Upside: +27.95%
Apr 13, 2026
Maintains: Neutral
Price Target: $165 → $160
Current: $160.30
Upside: -0.19%
Feb 25, 2026
Maintains: Neutral
Price Target: $80 → $60
Current: $46.18
Upside: +29.93%
Feb 6, 2026
Maintains: Overweight
Price Target: $255 → $225
Current: $167.90
Upside: +34.01%
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $45.69
Upside: +20.38%
Nov 25, 2025
Maintains: Overweight
Price Target: $165 → $180
Current: $114.96
Upside: +56.58%
Nov 7, 2025
Maintains: Underweight
Price Target: $26 → $22
Current: $11.86
Upside: +85.50%
Nov 5, 2025
Maintains: Neutral
Price Target: $14 → $16
Current: $15.71
Upside: +1.88%
Oct 30, 2025
Downgrades: Neutral
Price Target: $14 → $12
Current: $8.12
Upside: +47.78%
Oct 9, 2025
Maintains: Overweight
Price Target: $600 → $650
Current: $448.28
Upside: +45.00%
May 13, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $3.61
Upside: +66.20%
Oct 31, 2023
Maintains: Neutral
Price Target: $25 → $23
Current: $26.19
Upside: -12.18%